ARTICLE | Product Development
A Q&A with EVP of oncology R&D, Susan Galbraith: Part 1
By C. Simone Fishburn, Editor in Chief
July 20, 2024 12:16 AM UTC
AstraZeneca’s rise in oncology may turn out to be one of the industry’s big all-time turnaround stories. BioCentury sat down with one of its architects, Susan Galbraith, to discuss the factors behind the pharma’s growth in oncology, and where she sees cancer medicine headed from here.
In the first of a two-part Q&A, Galbraith discusses the critical decision points and the philosophy that has underscored the turnaround. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652988/oncology-at-astrazeneca-the-journey-to-the-top